PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 7840954

Correlation between ascorbate biosynthesis and ascorbate peroxidase activity.

M De Tullio·L De Gara·C Paciolla·O Arrigoni
View original source ↗Export metadata ↓

Abstract

The source did not provide an abstract. Follow the original record for more information.

Explore related subjects

Amaryllidaceae AlkaloidsAscorbate PeroxidasesAscorbic AcidHydrogen PeroxidePeroxidasesPhenanthridinesPlant ProteinsPlantsSugar AcidsJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M De Tullio, L De Gara, C Paciolla, O Arrigoni. Correlation between ascorbate biosynthesis and ascorbate peroxidase activity.. https://pubmed.ncbi.nlm.nih.gov/7840954/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1995

Antineoplastic agents, 294. Variations in the formation of pancratistatin and related isocarbostyrils in Hymenocallis littoralis.

By cloning Hymenocallis littoralis, a practical biosynthetic procedure was developed for producing pancratistatin [1]. The plant tissue culture-->greenhouse-->field production sequence was successively utilized for increasing an original 1.5 kg of wild H. littoralis bulbs to some 60,000 bulbs at present. In the central Arizona Sonoran Desert, the tropical H. littoralis was found to reach a maximum pancratistatin content in October and a minimum in May. Generally pancratistatin [1] was accompanied by lesser yields of narciclasine [2], 7-deoxynarciclasine [3], and 7-deoxy-trans-dihydronarcicasine [4]. Improved laboratory and pilot-plant scale techniques were also developed for the isolation of pancratistatin [1] from difficult-to-separate mixtures of narciclasine [2] and 7-deoxynarciclasine [3]occurring in H. littoralis.

Amaryllidaceae Alkaloids↗
PubMed1995

Antineoplastic agents, 301. An investigation of the Amaryllidaceae genus Hymenocallis.

Seven species (and one cultivated variety) of Hymenocallis (Amaryllidaceae) and the related Pancratium maritima, representing a broad geographical selection, were investigated as sources of pancratistatin [1] now undergoing preclinical development as an anticancer agent. Pancratistatin [1] was found to be a constituent of H. speciosa (Singapore), H. variegated (Singapore), H. pedalis (Seychelles), H. expansa (Bermuda), H. sonoranensis (Mexico), and P. maritimum (Israel). Only two species of Hymenocallis failed to yield one or more of the related cell-growth inhibitory isocarbostyrils such as narciclasine [3a], 7-deoxynarciclasine [3b], and 7-deoxy-trans-dihydronarciclasine [2].

Amaryllidaceae Alkaloids↗
PubMed1995

CRC/EORTC/NCI Joint Formulation Working Party: experiences in the formulation of investigational cytotoxic drugs.

The pharmaceutical formulation of a new anti-tumour agent has often been perceived as the bottleneck in anti-cancer drug development. In order to increase the speed of this essential development step, the Cancer Research Campaign (CRC), the European Organization for Research and Treatment of Cancer (EORTC) and the National Cancer Institute (NCI) agreed in 1987 to form the Joint Formulation Working Party (JFWP). The main goal of the JFWP is to facilitate the rapid progress of a new drug through pharmaceutical developmental to preclinical toxicology and subsequently to phase I clinical trial. Under the auspices of the JFWP around 50 new agents have been developed or are currently in development. In this report we present our formulation experiences since the establishment of the JFWP with a selected number of agents: aphidicolin glycinate, bryostatin 1, carmethizole, carzelesin, combretastatin A4, dabis maleate, disulphonated aluminium phthalocyanine, E.O.9, 4-hydroxyanisole, pancratistatin, rhizoxin, Springer pro-drug, SRI 62-834, temozolomide, trimelamol and V489. The approaches used and problems presented may be of general interest to scientists in related fields and those considering submitting agents for development.

Amaryllidaceae Alkaloids↗